I disagree. Any analysis that simpy tracks trailing quarters' numbers, without factoring in the projected sharp increases in revenue going forward as a result of the commercial roll-out of Nuedexta, is flawed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.